Niox Group plc (NIOX) ORD GBP0.0008

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Niox confirms approach from Keensight, enters formal offer period
20 March 2025 13:32
(Sharecast News) - Niox Group responded to media speculation on Thursday, confirming that it received a revised takeover proposal from Keensight Capital, valuing the medical device company at 81p per share.
-
Niox flags strong year, announces board changes
16 January 2025 14:13
(Sharecast News) - Asthma diagnosis and monitoring device specialist Niox Group reported a solid end to its financial year on Thursday, alongside news of significant board changes.
-
Niox reports solid first-half performance
24 September 2024 12:10
(Sharecast News) - Niox Group reported a solid first-half performance on Tuesday, with revenue increasing 12% to £21m, or 15% on a constant currency basis.
-
Niox revenue, earnings grow in H1
17 July 2024 10:48
(Sharecast News) - Medical devices business Niox said on Wednesday that both revenues and underlying earnings had grown in the six months ended 30 June.
-
Niox trading in line with expectations
22 May 2024 10:23
(Sharecast News) - Asthma-focussed medical device company Niox said in an update on Wednesday that it continued to perform strongly in the year to date, meeting management expectations.
-
Niox Group reports solid growth in final results
26 March 2024 14:33
(Sharecast News) - Niox Group reported a robust 18% increase in revenue in its final results on Tuesday, amounting to £36.8m compared to £31.3m in the prior year.
-
Niox Group flags solid revenue jump in 2023
18 January 2024 15:08
(Sharecast News) - Medical device company Niox Group said in a trading update on Thursday that it experienced substantial revenue growth in 2023, with a reported increase of 18% to £36.8m.
-
Niox posts growth amid business model transition
26 September 2023 13:40
(Sharecast News) - Asthma-focussed medical device developer Niox Group reported a robust 21% increase in first-half revenue on Tuesday, reaching £18.8m.
-
Niox Group describes very strong first-half
18 July 2023 09:07
(Sharecast News) - Asthma diagnosis and management device specialist Niox Group described a strong first-half in a trading update on Tuesday, with revenue growing 22% to around £18.8m.
Company announcements Announcements
-
Form 8.3 - Niox Group plc
28 March 2025 15:43
Niox Group
-
Form 8.3 - NIOX Group Plc
28 March 2025 14:19
Rathbones Group
-
Form 8.3 - Niox Group plc
28 March 2025 12:31
Niox Group
-
Form 8.3 - [NIOX Group plc]
28 March 2025 12:27
Niox Group
-
Form 8.5 (EPT/RI) - Niox Group plc
28 March 2025 11:27
Niox Group
-
Form 8.3 - NIOX Group plc
28 March 2025 11:18
Niox Group
-
Form 8.5 (EPT/RI)
28 March 2025 10:12
Niox Group
-
Form 8.3 - NIOX Group Plc
27 March 2025 14:13
Rathbones Group
-
Form 8.3 - NIOX Group Plc
27 March 2025 13:56
Niox Group
-
Form 8.3 - Niox Group plc
27 March 2025 12:37
Niox Group
-
Form 8.5 (EPT/RI) - Niox Group plc
27 March 2025 11:35
Niox Group
-
Form 8.3 - NIOX GROUP PLC
27 March 2025 10:32
Niox Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.